Shuanghuanglian Powder Injection (SHLPI) is an innovative traditional Chinese medicine powder injection derived from Shuanghuanglian Injection (SHLI). It addresses the limitations of the conventional dosage form, such as poor stability and easy degradation of active ingredients, and has been widely used in the clinical treatment of respiratory system infections and viral diseases. In recent years, there has been an increasing number of reports on its adverse reactions, including allergic reactions, raising widespread concerns regarding its quality controllability and medication safety. Focusing on elucidating the material basis and establishing a quality control system for SHLPI, this study retrieves and integrates relevant data to summarize the research advances in its chemical components, pharmacological mechanisms, and the application of quality control technologies. It also identifies current challenges such as unclear pharmacodynamic mechanisms of certain components and inadequate coverage of quality control standards. This work aims to provide insights for improving the quality stability and medication safety of SHLPI, as well as scientific references for the upgrading of quality standards and secondary development.

Shuanghuanglian Powder Injection  /  Shuanghuanglian Injection  /  material basis  /  quality control  /  safety  /  baicalin  /  chlorogenic acid  /  phillyrin